Aleksandra Maceski

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis.

Journal: JAMA neurology
Published: August 03, 2026

Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial.

Evolution of blood biomarkers reflective of brain tissue damage and inflammation in the perioperative course of intracerebral haemorrhage evacuation in a phase II proof-of-concept trial.

Journal: BMJ open
Published: June 25, 2026

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Serum Glial Fibrillary Acidic Protein and Retinal Neuronal Loss as Additive Prognostic Markers of Disability in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: May 13, 2026

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 23, 2026

PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery - protocol for an international, multicentre, prospective cohort study.

PRECISION study: impact of personalised cardiac anaesthesia and cerebral autoregulation on neurological outcomes in patients undergoing cardiac surgery - protocol for an international, multicentre, prospective cohort study.

Journal: BMJ open
Published: March 20, 2026

Neurofilament light chain and glial fibrillary acidic protein as potential early indicators of osmotic brain stress in hyponatremia and its correction.

Neurofilament light chain and glial fibrillary acidic protein as potential early indicators of osmotic brain stress in hyponatremia and its correction.

Journal: European journal of endocrinology
Published: March 01, 2026

The presynaptic protein bassoon is a biofluid biomarker of synaptic pathology in multiple sclerosis.

The presynaptic protein bassoon is a biofluid biomarker of synaptic pathology in multiple sclerosis.

Journal: EBioMedicine
Published: December 01, 2025

NfL and GFAP quantification and associations with mental health in recreational cannabis users-Results from the Swiss study on recreational cannabis access via pharmacies.

NfL and GFAP quantification and associations with mental health in recreational cannabis users-Results from the Swiss study on recreational cannabis access via pharmacies.

Journal: Molecular neurobiology
Published: November 23, 2025

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 17, 2025

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.

Journal: Brain : a journal of neurology
Published: June 14, 2025

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis.

Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 29, 2025

Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression.

Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression.

Journal: Communications medicine
Published: March 06, 2025
Showing 1-12 of 23

Last Updated: 09/26/2026